Abbott Will Present Two-Year Follow-Up Data At Xience FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Abbott expects to present two-year data for several hundred Xience V everolimus-eluting stent patients at a Nov. 29 meeting with an FDA advisory panel, the firm announced Oct. 17
You may also be interested in...
Panel Advises 5,000-Patient Postmarket Study For Medtronic’s DES
Medtronic should conduct a large postmarket study to monitor late stent thrombosis and help define the appropriate antiplatelet drug regimen for drug-eluting stent patients, FDA's Circulatory System Devices Panel recommended at its Oct. 10 meeting in Gaithersburg, Md
GE And Abbott Walk Away From $8 Billion Diagnostics Deal
Abbott says it will continue to manage its core laboratory and point-of-care diagnostics business for the long-term following the collapse of an $8.13 billion deal to sell the unit to General Electric
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.